Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon
Autore:
Alpaugh, RK; von Mehren, M; Palazzo, I; Atkins, MB; Sparano, JA; Schuchter, L; Weiner, LM; Dutcher, JP;
Indirizzi:
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA Fox Chase Canc Ctr Philadelphia PA USA 19111 , Philadelphia, PA 19111 USA
Titolo Testata:
MEDICAL ONCOLOGY
fascicolo: 3, volume: 15, anno: 1998,
pagine: 191 - 198
SICI:
1357-0560(199809)15:3<191:PITFMM>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; METASTATIC MELANOMA; GD3 GANGLIOSIDE; T-LYMPHOCYTES; INTERLEUKIN-2; PROLIFERATION; COMBINATION; CYTOTOXICITY; INTERFERON; EXPRESSION;
Keywords:
monoclonal antibody; R24; IL-2; alpha-IFN; melanoma;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Alpaugh, RK Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA Fox Chase Canc Ctr 7701 Burholme Ave Philadelphia PA USA 19111
Citazione:
R.K. Alpaugh et al., "Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon", MED ONCOL, 15(3), 1998, pp. 191-198

Abstract

The inflammatory tumor lymphocytic infiltrates and spontaneous tumor regressions seen in patients with metastatic malignant melanomas suggest a cellular immune involvement. Enhancement of such responses has been the goal of R24 (GD3 ganglioside-specific) monoclonal antibody trials, alone and in combination with other agents. This study reports the results of 21 patients treated in a phase IB trial employing R24 (0, 5, 25, 50 mg/m(2)) administered by continuous i.v. infusion on days 1-5 followed by 3 MU each of interleukin-2 (IL-2) and alpha interferon (alpha-IFN) given subcutaneously on days 8-12, 15-19 and 22-26. R24-related toxicities occurred pre-dominantly at the 25 and 50 mg/m(2) doses. One patient (50 mg/m(2) R24) exhibited a dose-limiting Grade 4 anaphylaxis. Cytokine-related toxicities required IL-2/alpha-IFN dose reduction in two patients and early termination of treatment in five additional patients. Nine of 20 baseline biopsies showed chronic inflammation; six with lymphocytic tumor infiltration and three where inflammation was confined to the perivascular/peritumoral spaces. No day 8 or 29 biopsies in the R24-treated groups demonstrated treatment-induced tumor lymphocytic infiltrates. However, one patient randomized to no R24 treatment, showed a significant inflammatory tumor lymphocytic infiltration at days 8 and 29. Eighteen of 21 treated patients were evaluable for response. One (5%) patient receiving IL-2/alpha-IFN alone had stable disease lasting 1.5 years. Five (28%) R24, IL-2/alpha-IFN-treated patients had stable disease ranging from 6 to 32 weeks, with one patient remaining alive 2.5 years post-treatment. Although this combined treatment program was generally well tolerated, no objective responses were seen and significant R24-induced tumor lymphocytic infiltrates were not demonstrated.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 10:26:02